Endogenously produced antibody against *Streptococcus pneumoniae* serotype 19A capsular polysaccharide

Endogenously produced antibodies against *Streptococcus pneumoniae* serotype 19A are naturally occurring immunoglobulins generated in response to infection or vaccination. They specifically recognize glycan epitopes present on the capsular polysaccharide of serotype 19A, a highly invasive and increasingly multidrug-resistant strain of *S. pneumoniae*. These antibodies facilitate bacterial clearance by promoting complement activation and phagocytosis, reducing risk and severity of pneumococcal diseases such as pneumonia and meningitis. Their generation is the desired outcome of pneumococcal conjugate vaccination, with serum titers serving as biomarkers of protective immunity[1][3][5][6][7][8].

Other names

Anti-*Streptococcus pneumoniae* type 19A antibodyAnti-19A capsular polysaccharide antibody19A CPS antibody

Vaccination induces antibody production targeting 19A capsule glycan structures[1][5]. These antibodies mediate protection through opsonization, enhancing complement-mediated killing and phagocytosis[3][5].